Aktie A2QJX0 FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Frazier Lifesciences Acquisition Corporation

Aktien

A2QJX0

KYG3710A1058

FLAC

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib
Frazier Lifesciences Acquisition Corporation Announces Executive Changes
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients
Frazier Lifesciences Acquisition Corporation(NasdaqCM:FLAC) dropped from NASDAQ Composite Index
NewAmsterdam Pharma B.V. completed the acquisition of Frazier Lifesciences Acquisition Corporation from a group of shareholders in a reverse merger transaction.
Frazier Lifesciences Acquisition Corporation shareholders approve business combination with NewAmsterdam Pharma Holding B.V
FRAZIER LIFESCIENCES ACQUISITION CORP : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Frazier Lifesciences Shareholders Approve Merger With NewAmsterdam Pharma Holding
Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.
Frazier Lifesciences Acquisition : shareholders approve business combination with NewAmsterdam Pharma Holding B.V.
FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger - Form 8-K/A
FRAZIER LIFESCIENCES ACQUISITION CORP Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)
NewAmsterdam Pharma to Go Public in Deal With Frazier Lifesciences SPAC
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger - Form 8-K
FRAZIER LIFESCIENCES ACQUISITION CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QJX0 Aktie
  4. Nachrichten Frazier Lifesciences Acquisition Corporation
  5. Andere Sprachen